Workshop on use of intravenous immunoglobulin in hand, foot and mouth disease in Southeast Asia.

Abstract

The South East Asia Infectious Disease Clinical Research Network convened subject matter experts at a workshop to make consensus recommendations for study design of a clinical trial for use of intravenous immunoglobulin (IVIg) in severe hand, foot and mouth disease (HFMD). HFMD is a highly contagious emerging infection among children in the region, a small proportion of whom develop neurologic and cardiopulmonary complications with high case-fatality rates. The use of IVIg for treatment of severe disease is widespread and a part of local, national, and international guidelines, but no clinical evidence warrants the use of this drug, which is expensive and has potentially serious side effects. During a 2-day workshop in March 2014, a group of HFMD experts reviewed the current evidence related to use of IVIg in HFMD and discussed potential study design, feasibility, inclusion and exclusion criteria, sample size, primary and secondary endpoints, and subsidiary studies for a randomized, placebo-controlled trial.

• Authors: Sokkosal Chea, Yi-Bing Cheng, Kulkanya Chokephaibulkit, Tawee Chotpitayasunondh, H Rogier van Doorn, Zen Hafy, Surinda Kawichai, Ching-Chuan Liu, Nguyen Tran Nam, Mong How Ooi, Marcel Wolbers, Mei Zeng
• Journal: Emerging infectious diseases (Emerg Infect Dis) Vol. 21 Issue 1 (Jan 2015) ISSN: 1080-6059 [Electronic] United States
• PMID: 25531166 (Publication Type: Consensus Development Conference, Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Immunoglobulins, Intravenous

Topics

• Asia, Southeastern
• Hand, Foot and Mouth Disease (drug therapy)
• Humans
• Immunoglobulins, Intravenous (therapeutic use)
• Randomized Controlled Trials as Topic